Our platform uncovers the genes that matter most — and then turns them into tools to reprogram T cells.
First–in–human anticipated H1 '27
Candidate nomination anticipated H1 '27
Our lead program OVT-101 is a first-in-class investigational off-the-shelf chimeric antigen receptor (CAR) T cell therapy for ovarian cancer powered by OverT genetic programming technology.
OVT-101 targets claudin 6 (CLDN6), which is present in the majority of ovarian cancers — and several other solid tumors — but absent from healthy tissues. In addition to the CAR, we genetically re-program T cells to overcome the suppressive tumor microenvironment of ovarian cancer and increase their durability to enable a superior response. OVT-101 uses gamma delta (γδ) T cells derived from healthy donors, making the therapy more accessible to patients. γδ T cells may present both an improved safety profile and enhanced tumor targeting compared to the current standard: engineered autologous alpha beta T cells. OverT has developed a highly optimized γδ T cell expansion process that enables production of many doses from a single manufacturing run.
Our second program OVT-201 is a first-in-class investigational off-the-shelf cell therapy for solid tumors. It uses a broadly cancer-reactive, naturally occurring gamma delta (γδ) T cell receptor (TCR) and OverT genetic programming technology.
OVT-201 is an off-the-shelf γδ T cell product utilizing the same highly-optimized manufacturing process and genetic programming as our lead program, OVT-101. For cancer targeting, it uses a γδ TCR selected from cancer patients for broad solid tumor targeting via a novel protein antigen. OVT-201’s γδ TCR does not depend on any particular major histocompatibility complex (MHC) for targeting and can be used to treat any patient.
.webp)
We are continuously building on our discovery platforms to push the boundaries of cell therapy. We have developed purpose-built artificial intelligence (AI) models trained on OverT’s deep dataset of gene-to-function maps from primary immune cells across therapeutic contexts — encompassing millions of gene x phenotype measurements. By learning from these deep datasets, our next-generation programs capitalize on combinations of genes for advanced reprogramming and also incorporate genetic programs not found in nature. These discovery platforms are the key to overcoming challenges for cell therapy across the spectrum of solid cancers.
Most cell therapies have had to be made for each patient individually, resulting in long waiting times and making it more difficult to ensure the quality of each treatment.
With our proprietary manufacturing process, we are able to make thousands of doses of therapeutic gamma delta T cells in a single manufacturing run. These engineered cells pass a stringent quality control step to ensure consistent activity and are ready to deploy fast when the patient needs them.
.webp)
